Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of ZEN003694 (ZEN-3694) in Combination With Capecitabine in Patients With Solid Tumors

NCT05803382 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05803382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05803382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of ZEN003694 (ZEN-3694) in Combination With Capecitabine in Patients With Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
November 8, 2023
Completion date
June 30, 2027
Enrollment
30 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal carcinoma, metastatic malignant solid neoplasm, stage iv colorectal cancer ajcc v8, unresectable colorectal carcinoma, unresectable malignant solid neoplasm